Monday, July 23, 2012
Cubist Pharmaceuticals Inc., of Lexington, Mass., reported second-quarter revenues of $230.6 million, and earnings per share of 58 cents, solidly beating analyst estimates of 45 cents per share. The company reported net revenues of $212 million for antibiotic Cubicin (daptomycin), an increase of 20 percent over the second quarter of 2011.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.